2nd Aug 2019 – The Global Head
and Neck Cancer Drugs/Therapeutics Market was valued at USD 752.5
million in 2016 and is estimated to grow significantly in the coming years
owing to the development of cost-effective and innovative Head and Neck Cancer
treatments. Cancers of squamous cells present in the linings of larynx, nose,
salivary glands, throat, lips, and mouth cause the Head and Neck Cancers. The
Head and Neck Cancer is amongst the common type of cancers. The past records
reveal that every year a massive number of Head and Neck Cancers are detected
globally with more than half accounting to death annually. The increasing
number of Head and Neck Cancer patients and the demand for cost-efficient
treatment options are helping the Head and Neck Cancer Drugs/Therapeutics
Market to grow with a CAGR of 9.4%.
The most preferred therapy performed by
the surgeons is the surgical therapy combined with the radiation therapy.
Moreover, the present treatment options available for Head and Neck Cancer
results in less chances of survival rate. The latest developments in advanced
radiotherapy and chemotherapy has helped to preserve some functions of the
face. The treatment for Head and Neck Cancer is a significant challenge for the
surgeons since the choice of treatment differs from patient to patient and
tumor location. Generally, the Head and Neck Cancers are operated with the
surgery, but the complicated facial structures and functions restricts the
surgical operations. However, more focus is now being given to the
technological developments of new targeted molecules like gene therapy,
antibody drug conjugates, monoclonal antibodies, etc. This is expected to widen
the market opportunities in near future, which will fuel up the market growth.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/head-neck-cancer-drugs-therapeutics-market/request-sample
The market categorized on the grounds of
treatment type, disease indication, end user and geography. On the grounds of
treatment type, the market is distributed into Chemotherapy, Radiation Therapy,
External Radiation Therapy, Internal Radiation Therapy, Surgery and Targeted
Therapy. Surgery, bring the most preferred therapy choice is projected to lead
the Head and Neck Cancer Drugs/Therapeutics Market in the forecast period. To
prevent the reoccurrence of the cancer, the Radiation therapy is used which is
expected to contribute largely to the market after the surgery. Furthermore,
Chemotherapy is an assistant treatment to other therapies and therefore is
expected to contribute little share in the Head and Neck Cancer
Drugs/Therapeutics Market.
On the grounds of disease indication,
the market is distributed into Laryngeal Cancer, Lip and Oral Cavity Cancer,
Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer and etc. The
Lip and Oral Cavity cancer is predicted to rise globally due to growing number
of people affected by lip and oral cancer. On the grounds of end user, the Head
and Neck Cancer Drugs/Therapeutics Market is distributed into Hospitals,
Specialty Clinics and Ambulatory Surgical Centers. Hospital is expected to
contribute a comparatively larger share.
Geographically, the market is segmented
as North America, Latin America, Europe, Asia Pacific and Middle East &
Africa. The Head and Neck Cancer Drugs/Therapeutics Market share from North
America will continue to dominate due to high prevalence high smoking rate and
HPV-induced cancers. After this, Europe is expected to contribute second
largest market share. The leading players in the Head and Neck Cancer
Drugs/Therapeutics Industry are profiled as Merck & Co. Eli Lilly, Merck
Group and Bristol-Myers Squibb, Sanofi.
For
More Details, Visit @ http://www.millioninsights.com
No comments:
Post a Comment